Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sharfstein Heads FDA Transparency Task Force

Executive Summary

FDA's formation of an internal "Transparency Task Force" is a savvy approach that allows agency leaders to begin making good now on their pledges to enhance openness while giving them six months to decide whether to release any specific new information

You may also be interested in...



Biosimilar Labeling Needs Greater Transparency, BIO And PhRMA Say

Need for informed prescribing demands that products include the data that support biosimilarity, trade groups say in joint petition.

FDA Gets Investor Advice On Transparency At White House Gathering

FDA recently met with venture capitalists and drug industry leaders to discuss the agency's initiative to become more transparent. While such get-togethers are not unusual, the location of this one signaled how significant the topic is to FDA. Rather than meet at the agency's still-being-renovated headquarters in White Oak, participants gathered at the White House

FDA Gets Investor Advice On Transparency At White House Gathering

FDA recently met with venture capitalists and drug industry leaders to discuss the agency's initiative to become more transparent. While such get-togethers are not unusual, the location of this one signaled how significant the topic is to FDA. Rather than meet at the agency's still-being-renovated headquarters in White Oak, participants gathered at the White House

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS051153

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel